Trefoil Therapeutics has raised $28 million in Series A financing, which will be used to support its phase 2a proof-of-concept study in corneal endothelial dystrophy, the company announced in a press release.
The financing was led by Bios Partners, with Access Biotechnology, Hatteras Venture Partners, Aju IB Investment, Correlation Ventures, ExSight Ventures and InFocus Capital Partners participating as well.
TTHX1114, the company’s lead product candidate, is a form of the FGF-1 protein designed to reverse vision loss by stimulating endothelial cell proliferation and migration, the
Uncategorized